Rare diseases
Investigational molecules
Locations
359 conditions with trials, the busiest first
849 trials across Europe, recruiting first
Study of L19IL2 and L19TNF for Patients with Skin Cancer Suitable for Direct Tumor Injection
FranceStudy on Canakinumab for Patients with PAPA Syndrome
ItalyStudy of Cemiplimab Alone and with RP1 for Patients with Advanced Skin Squamous Cell Carcinoma
BulgariaStudy on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients
FranceStudy of RO7247669 at Different Doses for People with Previously Untreated Advanced Melanoma that Cannot be Removed by Surgery or Has Spread
CzechiaStudy on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy
BelgiumStudy on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis
FranceStudy on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid
BulgariaStudy of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery
AustriaStudy on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines
BulgariaStudy on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials
BelgiumStudy on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy
FranceThe therapies tested most often in Skin and subcutaneous tissue disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
